Mutations in the enzyme cytosolic isocitrate dehydrogenase 1 (IDH1) are a common feature
of a major subset of primary human brain cancers. These mutations occur at a single amino …

… ng ml −1 EGF, 10 μg ml −1 insulin, 100 ng ml −1 cholera toxin, 0.5 mg ml −1 hydrocortisone,
100 U ml −1 penicillin/streptomycin, and labelled/unlabelled … Vander Heiden … Vander Heiden …

… MG Vander Heiden et al. addressed the question of why a cell would "choose" glycolysis …
The question posed by Vander Heiden et al., "why do proliferating cells switch to a less efficient …

Most tumors exhibit increased glucose metabolism to lactate, however, the extent to which
glucose-derived metabolic fluxes are used for alternative processes is poorly understood 1 , 2 …

… for 5 days at 25 mg kg −1 for FDG uptake or once at 75 mg kg −1 3 h before 18 F-Gln injection.
Rapamycin treatments were administered intraperitoneally daily for 4 days at 2 mg kg −1 …

Our understanding of how the RAS protein family, and in particular mutant KRAS, promotes
metabolic dysregulation in cancer cells has advanced substantially over the last decade. In …

Aberrant activation of the mammalian target of rapamycin complex 1 (mTORC1) is a common
molecular event in a variety of pathological settings, including genetic tumor syndromes, …

Genetic events in cancer activate signalling pathways that alter cell metabolism. Clinical
evidence has linked cell metabolism with cancer outcomes. Together, these observations have …

Warburg's observation that cancer cells exhibit a high rate of glycolysis even in the presence
of oxygen (aerobic glycolysis) sparked debate over the role of glycolysis in normal and …

Macropinocytosis is a highly conserved endocytic process by which extracellular fluid and
its contents are internalized into cells through large, heterogeneous vesicles known as …